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Abstract We developed a detailed, whole-body physio-
logically based pharmacokinetic (PBPK) modeling tool for
calculating the distribution of pharmaceutical agents in the
various tissues and organs of a human or animal as a
function of time. Ordinary differential equations (ODEs)
represent the circulation of body ﬂuids through organs and
tissues at the macroscopic level, and the biological trans-
port mechanisms and biotransformations within cells and
their organelles at the molecular scale. Each major organ in
the body is modeled as composed of one or more tissues.
Tissues are made up of cells and ﬂuid spaces. The model
accounts for the circulation of arterial and venous blood as
well as lymph. Since its development was fueled by the
need to accurately predict the pharmacokinetic properties
of imaging agents, BioDMET is more complex than most
PBPK models. The anatomical details of the model are
important for the imaging simulation endpoints. Model
complexity has also been crucial for quickly adapting
the tool to different problems without the need to generate
a new model for every problem. When simpler models
are preferred, the non-critical compartments can be
dynamically collapsed to reduce unnecessary complexity.
BioDMET has been used for imaging feasibility calculations
in oncology, neurology, cardiology, and diabetes. For this
purpose, the time concentration data generated by the
model is inputted into a physics-based image simulator to
establish imageability criteria. These are then used to
deﬁne agent and physiology property ranges required for
successful imaging. BioDMET has lately been adapted to
aid the development of antimicrobial therapeutics. Given a
range of built-in features and its inherent ﬂexibility to
customization, the model can be used to study a variety of
pharmacokinetic and pharmacodynamic problems such as
the effects of inter-individual differences and disease-states
on drug pharmacokinetics and pharmacodynamics, dosing
optimization, and inter-species scaling. While developing a
tool to aid imaging agent and drug development, we aimed
at accelerating the acceptance and broad use of PBPK
modeling by providing a free mechanistic PBPK software
that is user friendly, easy to adapt to a wide range of
problems even by non-programmers, provided with ready-
to-use parameterized models and benchmarking data col-
lected from the peer-reviewed literature.
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Introduction
As David Leahy passionately argues in his 2004 review,
complex engineering tasks these days are unthinkable
without the use of computer-based simulation methods to
design and test every aspect of a complex system before it
is built. Similarly, the use of mathematical models of a
human should be just as a standard and integral part of a
pharmaceutical development process. Trial and error
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cient. Replacing them with rational, streamlined, and
therefore more efﬁcient design processes requires realistic
and validated models [1]. Mechanistic, whole-body phys-
iologically based pharmacokinetic (PBPK) models are the
closest to a virtual human with compartments representing
the organs, tissues, cells and sub-cellular compartments
and with ﬂows between them corresponding to the circu-
lating body ﬂuids.
The pharmaceutical industry has long recognized that
physico-chemical properties determine the pharmacoki-
netics and pharmacodynamics of drugs [2]. Signiﬁcant
effort has gone into determining the ADME properties of
compounds experimentally, then into developing compu-
tational tools to predict them from chemical structure alone
[3]. This enabled the elimination of compounds with
unfavorable properties, thus decreasing the number of
failures later in the drug development process. The in vitro
generated ADMET properties can be made more predictive
of therapeutic outcome by incorporating them into a system
model to reveal their quantitative contribution and relative
importance in vivo. PBPK models are designed to integrate
information about the pharmaceutical agent with the
physiology properties of the host and predict the distribu-
tion of the compound in organs and tissues over time. At
later stages, they can be used to optimize dosing and
evaluate the performance of the agent in a diverse popu-
lation. The greatest advantage of PBPK models over sim-
pler compartmental PK models is the fact that the
parameters of the former have meaning, they represent
well-deﬁned properties of the system. Because of this, it
becomes possible to identify factors responsible for the
undesired behavior of a compound and change the behavior
by altering speciﬁc properties [4].
The environmental health ﬁeld was an early adopter of
PBPK modeling to assess the risk of exposure to industrial
pollutants and toxins [5, 6]. The pharmaceutical commu-
nity has been slower to embrace the routine use of PBPK
models. This might have been due in part to the complex
nature of these models, which can require signiﬁcant time
and effort to implement and can be difﬁcult to validate. The
initial lack of software that could easily build and solve
PBPK models likely contributed to the slow adoption of
these methods within the pharmaceutical community,
which instead predominantly turned to simpler modeling
methods and allometric scaling rules to address their
questions [7, 8]. However, several factors are now creating
an environment in which PBPK models can become
powerful, robust tools for the development of pharmaceu-
ticals. First, the pharmaceutical industry is forced to look
for ways to cut costs in the drug discovery and develop-
ment process. The acceptance and broad application of
PBPK models in early drug discovery and other phases of
pharmaceutical development is one way to achieve
improved productivity [1, 4, 9, 10]. Second, the increasing
use of imaging studies and radio-labeled drug analogues
during pharmaceutical development provides an opportu-
nity to sample multiple organ tissues rather than just blood
and urine in a nondestructive manner [11, 12]. This data
can be used to test and validate PBK models. Thirdly,
biological measurements are becoming more quantitative
and there is an ever-increasing depth of knowledge about
pathophysiology, both of which will improve the physiol-
ogy parameters needed to populate the models. Lastly, the
computer technology and infrastructure exists to create a
ﬂexible environment for easy implementation of PBPK
models along with mechanisms for the sharing and con-
tinuous improvement of the tool by a user community.
The increasing interest in PBPK modeling is well
reﬂected by the growing number of publications with this
topic both for pharmaceutical and environmental toxicol-
ogy applications [9]. A number of informative reviews
have been published on recent developments and applica-
tion of PBPK modeling in the preclinical and clinical
phases of drug development, as well as environmental
toxicology [10, 13–19]. In spite of the increase in the
application of PBPK models, there remains a need for their
critical and rigorous evaluation [20]. This includes
assessing the predictive capacity of PBPK models with test
data and clear model documentation as well as performing
sensitivity, variability, and uncertainty analyses to improve
the credibility and acceptance of PBPK models [5]. Our
work is aimed at addressing these needs in part through its
open framework for communication and sharing of the
PBPK model, parameters, and test data.
The requirement for efﬁcient pharmaceutical develop-
ment exists not only in the drug industry but also in
companies developing imaging agents, which share many
of the same scientiﬁc and productivity challenges as
pharmaceutical companies [21, 22]. Imaging agents them-
selves are like drugs in many ways and they are expected to
have similar ADMET proﬁles for proper solubility, mem-
brane permeability, etc. One important difference is that
imaging agents, in order to produce a sharp image, have to
reach and maintain high enough concentrations in the tis-
sues of interest relative to the surrounding areas within the
narrow time frame available for image acquisition. This
makes pharmacokinetics a critical issue for imaging agents
[23–26]. Another distinctiveness of imaging agent devel-
opment is the need of detailed knowledge and representa-
tion of the anatomical structures to be imaged. These
factors have motivated the development of our detailed,
whole-body PBPK modeling tool.
In this article, we describe the physiology model and the
computer implementation of the PBPK simulator that
forms the core of BioDMET. The main features of the
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the results of testing and validation. Finally, applications of
BioDMET to two main areas are outlined. The tool is
provided with detailed whole-body PBPK models of
human, monkey, guinea pig, rat and mouse with the pos-
sibility of user-implemented adjustments for age, body
weight, gender, and health condition. It also contains
examples of drug/agent models as well as a validation
dataset consisting of calculated biodistribution data of a
number of agents in various tissues and organs compared to
published experimental values. While developing a
detailed PBPK tool to aid imaging agent and drug devel-
opment, we strove to address the perceived gaps in the
existing tools [27–42] and to accelerate the acceptance and
broad use of mechanistic PBPK models by providing (1) a
free, mechanistic PBPK software that can be quickly and
easily adapted to the speciﬁcs of a wide range of problems
even by non-programmers, (2) ready-to-use physiological
and anatomical parameters for multiple species, strains,
gender, and age, and (3) easily accessible test data to
benchmark the predictive accuracy and conﬁdence levels
of PBPK models.
Methods
The BioDMET model structure
BioDMET enables the quick generation of complex multi-
compartment pharmacokinetic models that use ODEs to
represent, at the macro scale, the circulation of ﬂuid
through organs and tissues, and, at the molecular scale, the
biological transport mechanisms and biotransformations
within cells and their organelles. This is accomplished by
ﬁrst deﬁning the BioDMET model structure composed of:
(1) a whole body model that includes all of the ﬂuid spaces
and their associated ﬂows; (2) an element model comprised
of the molecules, receptors, transporters, pathogens, and
their interactions that are explicitly modeled, and ﬁnally;
(3) the simulation setup parameters that specify the sam-
pling time points, administration methods and starting
concentrations for all the elements of interest. Once the
complete BioDMET model structure is deﬁned, the soft-
ware tool automatically sets up the required pharmacoki-
netic compartments and the ODEs representing the ﬂows
between compartments. The ODEs are then solved to
generate the concentration over time curves for the relevant
elements in the model.
The whole body model
The whole body or animal model in BioDMET is a col-
lection of ﬂuid spaces and connections between them:
surfaces and pipes with convective ﬂows of blood and
lymph. The model is hierarchical in nature where ﬂuid
spaces are contained within cells and tissues, which are
components of the organ systems. All major organs are
included, each being composed of one or more tissues
(Fig. 1). Although some tissues have unique features, a
generic tissue is composed of a vasculature space, an
interstitial space, and cells (Fig. 2). Within each tissue,
there are ﬁxed tissue-speciﬁc and endothelial cells, as well
as mobile blood cells. Multiple different cell types can be
deﬁned within a tissue. For example, the endocrine tissue
of the pancreas (excluding the vasculature) is composed of
*65% insulin secreting beta cells, *17% glucagon
secreting alpha cells, *9% somatostatin secreting delta
cells and 9% pancreatic polypeptide secreting cells [43].
Each cell is further divided into a number of spaces cor-
responding to the cytosol, endosomes, Golgi, and other
organelles. The ﬂuid in each space has its own unique set
of properties including pH, composition (e.g., water, pro-
tein, carbohydrate, lipid, DNA, RNA, mineral, gas), and
the center-to-edge diffusion length characteristic of the
space. While these details add complexity to the model,
they are crucial to answering questions about mechanisms
and feasibility assessment in the earliest stages of molec-
ular imaging R&D.
A space can be connected to one or more other spaces
by pipes and surfaces (Fig. 1b). Pipes correspond to ﬂuid
ﬂow between spaces and are characterized by a ﬂow rate
and the direction of ﬂow. One example of a pipe connec-
tion is between the vasculature space of a tissue (e.g.,
capillary beds) and the vasculature space of the major
artery or vein tissues of the cardiovascular system. Another
example of a pipe connection is the one between the bile
space of the liver and the bile space of the gallbladder that
represents the bile ducts. Surface connections are the
equivalents of membranes, such as the one between a cell’s
cytosol and the surrounding interstitial space. Some cells in
the model are polarized, having two surfaces, which cor-
respond to the basal and the apical plasma membranes.
Examples include the epithelial cells lining the proximal
tubules of the kidney, the hepatocytes of the liver, and the
endothelial cells of the capillaries. The properties of a
surface connection include the surface area, thickness, and
composition. A surface can also have a distribution of
pores that have a given dimension, charge, and fractional
area of the surface. Examples of pores include the glo-
merular pores in the endothelial cells of the kidney.
Another example of a surface with pores is the nuclear
membrane.
The parameters for the whole body model were deﬁned
to facilitate easy scaling of the model’s volumes and ﬂows.
While each tissue has an absolute volume, the cells and
ﬂuid spaces contained within the tissue are deﬁned with a
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child hierarchal tree. By changing the total volume of the
tissue causes an instantaneous change in the volume of the
vasculature, interstitial space, cells and ﬂuid spaces con-
tained within the tissue. The composition (e.g., volume
fraction water, protein, lipid, etc.) of each of the ﬂuid space
is deﬁned within the model and is used to convert between
volumes and masses for the tissues, cells, and ﬂuids of the
body.
The ﬂow rates between spaces have also been set up to
allow easy scaling of a model. For example, the arterial
blood ﬂow to a tissue is deﬁned in terms of volume of ﬂow
per time per volume of tissue, while the venous and lymph
ﬂows of the tissue are deﬁned relative to the arterial blood
Fig. 1 a The BioDMET whole
body model is a hierarchical
structure of all major organs and
organ systems (green
hexagons), each composed of
one or more tissues (orange
quadrangles). b The tissues are
made of cells (purple octagon)
and spaces (blue rectangle). The
spaces are connected by pipes
(magenta lines) representing
blood or lymph ﬂow and by
surfaces (blue lines). The
arrows on the magenta lines
show the direction of the pipe
ﬂow. A dotted line means that
the space at one end of the
connection is collapsed in the
hierarchical view. When a space
is selected at the GUI
(Interstitial currently), its
connections to the rest of the
system are automatically shown
Fig. 2 Tissue and cell structure
with the types of transport
processes modeled in
BioDMET
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matic scaling of the tissue’s blood and lymph ﬂow in the
correct proportions. The ﬂow of the chime, bile, pancreatic
juice, or CSF is deﬁned in a similar manner. However, the
software tool allows the user to override any of the default
or scaled parameter values of the whole body model.
The element model
Elements within BioDMET are deﬁned to explicitly model
molecules, receptors, transporters, and even pathogens
within the whole body model (Fig. 3). Each element type
or class has a set of properties to deﬁne its behavior. The
agent administered to the animal is perhaps the most
important element of the model. The agent can be com-
posed of one or multiple molecules (e.g., a drug and its
metabolites). BioDMET has been used to study the bio-
distribution of molecules that range in molecular weights
from small molecules (\1 kDa) to medium peptides
(1–60 kDa) to large proteins ([60 kDa) and particles. The
size of the molecule changes its permeability and clearance
characteristics as determined by the physics-based equa-
tions in the model. Other relevant physico-chemical
properties include the molecule’s charges and pH com-
partmental effects (captured by the LogD), which inﬂuence
its membrane permeability and tendency to partition into
lipid or aqueous spaces. The plasma protein binding and
liver microsomal clearance rate are additional properties
that are required as input.
Receptors, transporters, and biotransformation reactions
are also part of the element model. They can be included by
specifying enzyme concentrations, sub-cellular locations,
substrates, and kinetic rates. The tool makes it possible to
calculate the inﬂuence of the competitive effects of
receptor saturation and molecular transport on a molecule’s
biodistribution. This can be done for both endogenous
substances and metabolites of the parent molecule. The
capability to model multiple metabolites of the parent
molecule has been used to understand the loss in imaging
contrast in speciﬁc tissues. It can also be used to model
metabolite-induced toxicity of drugs.
Elements can be set up to interact with each other such
as the binding between a molecule and a receptor. Another
example of an element interaction is the conversion of one
molecule into two other molecules (e.g., cleavage) by a
biotransformation enzyme.
Fig. 3 The components of the
BioDMET Model: Animal,
Elements, Administer, and
Sampling. The element model
deﬁnes the molecules, receptors,
transporters, and their
interactions that are explicitly
modeled. The green lines show
the interactions between
elements and their locations
within the animal model. Pink
lines are for the injection
properties. A dotted line means
that the space for one end of the
connection is collapsed in the
hierarchical view. Only the
interactions for the current
selected element (GLP-1 Binder
is currently selected) are shown
at a given time
J Pharmacokinet Pharmacodyn (2012) 39:37–54 41
123Simulation run parameters
Information about the dose, administration method (oral,
intravenous, subcutaneous, or intramuscular), number of
administrations, and sampling time points are captured
under the Administer and Sampling components of the
model (Fig. 3). In addition to the existing standard tissue
spaces, a set of sampling locations are deﬁned by merging
several anatomical spaces and averaging the simulated
element concentrations in them. For example, the sapling
location Brain includes the white matter, the grey matter
and the ventricles. The sampling location Small intestine
includes the duodenum, the two segments of the jejunum
and the three segments of the ileum. User-deﬁned sampling
locations are also enabled.
Initializing the PBPK compartmental model and ODEs
Besides the spaces and elements described above,
BioDMET utilizes the concepts of entity and compartment
in ways that might differ from the traditional PK nomen-
clature. An entity is a discrete unit, which, at least in the-
ory, is distinguishable and measureable. If a molecule and
its receptor are deﬁned elements of the current model, there
are a total of three entities: the unbound molecule, the free
receptor, and the bound molecule-receptor complex. A
compartment is deﬁned as the unique pair of an entity and a
ﬂuid space. In theory, an entity could be present in any of
the ﬂuid spaces deﬁned in the whole body model. Thus if
the BioDMET model has 3 deﬁned entities and 789 ﬂuid
spaces, there could be 2,367 unique compartments. How-
ever, due to various barriers to transport and interactions
between entities, the entity concentration is zero in a large
number of the compartments. For example, if the receptor
of a molecule is deﬁned to be present in the beta cell
membranes of the endocrine pancreatic tissue, that receptor
and the corresponding molecule-receptor complex will
have zero concentrations in all other spaces. At the
beginning of each simulation, the software generates a list
of all possible entities, ﬂow equations, and compartments.
It then determines which compartments could have non-
zero entity concentrations at some time point of interest.
These compartments and their corresponding ﬂow equa-
tions deﬁne the full PBPK model for that particular
simulation.
In order for the tool to be non-restrictive in its scope and
ready to use for a variety of projects, the BioDMET model
must be detailed in the compartments that are predeﬁned
with their physiological parameters available in the data-
base (Figs. 1, 2). This richness in details comes at a cost of
computational time when working with hundreds of com-
partments. We have devised a method and algorithm that
allows some compartments to be collapsed and
approximated when they do not signiﬁcantly impact the
results of the simulation. The collapsing of compartments
is done just prior to submitting the BioDMET PBPK model
to the ODE solver. At the end of the calculation, the solver
results are translated (expanded) back to the rich com-
partment model view. This collapsing process is not visible
to the user although it is possible to customize what
compartments are collapsed at the GUI.
Model equations
Hundreds of differential equations have to be solved to
simulate the biodistribution of a molecule in a BioDMET
whole body model. All of these differential equations are
associated with a limited number of event types such as the
administering of a molecule to a ﬂuid space, binding of the
molecule to a receptor, biotransformation of the molecule
into another form, and transport of the molecule from one
ﬂuid space to another. To provide some illustrative
examples, the differential equations describing several
modes of transport are presented below.
The simplest form of transport is the convective ﬂow of
an entity between two ﬂuid spaces connected by a pipe. An
example is the vasculature space of the main arteries with
the vasculature space of a tissue. Assuming ﬂow occurs
from space 1 to space 2, the change in concentration of an
entity (C1 and C2) per unit time in the two ﬂuid spaces is a
function of the ﬂow rate (J1?2) and the volumes of the
spaces (V1 and V2) as described by Eqs. 1a and 1b.
dC1
dt
¼ 
J1!2C1
V1
ð1aÞ
dC2
dt
¼
J1!2C1
V2
ð1bÞ
A more complex form of convective ﬂow occurs through
pores that may limit the ﬂow of an entity based on its size.
For example, the pores found in the kidney glomerular
capillaries act as a ﬁlter for the ﬂuid that ﬂows from the
vasculature space through the fenestrated endothelial cells
of the glomeruli and into the lumen space of the renal
tubules. In BioDMET, this type of situation is modeled by
connecting the two ﬂuid spaces, the capillary vasculature
space and the renal tubule lumen space with both a pipe
and a surface connection. The pipe deﬁnes the convective
ﬂow from the one space to the other and the surface
connection deﬁnes the type, size, and fractional area of the
pores of the fenestrated endothelial cells. Equations 2a–2c
describe this ﬁltered convective ﬂow process. Note that the
total convective ﬂow, J1?2, is multiplied by a summation
term over all pores. The summation term includes the
pore’s fractional surface area, /i, and the reﬂection
coefﬁcient, ri, of the entity trying to pass through the
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entity and pore combination, and is mainly dependent
upon the entities’ hydrodynamic radius, Rh, and the pore
radius, rpore (Eq. 2c). This relationship can be used when
there are no charge–charge interactions or they are
negligible [44].
dC1
dt
¼ 
J1!2
Ppores
i¼1 Ui 1   ri ðÞ
  
C1
V1
ð2aÞ
dC2
dt
¼
J1!2
Ppores
i¼1 Ui 1   ri ðÞ
  
C1
V2
ð2bÞ
k ¼
Rh
rpore
k\1 r ¼ 1  
ð1   kÞ
2ð2  ð 1   kÞ
2Þ 1   k
3
  
1   k
3 þ 2k
2
3
k 1 r ¼ 1
8
> > > <
> > > :
ð2cÞ
A third type of ﬂow is the passive diffusion of an entity from
one ﬂuid space to another by crossing a surface. A classic
example is the passive diffusion of a molecule from the
interstitial space of the tissue into the cytosol of the cell
acrossitsplasmamembrane(Eqs. 3a–3f).Theconcentration
changes in the two neighboring spaces depend on the
permeability rates (P1?2,P 2?1), the partition coefﬁcient
(Kp), and the surface area separating the spaces (S12). Note
thatforneutralmolecules,thepermeabilityrateisthesamein
both directions (P1?2 = P2?1). The partition coefﬁcient Kp
(Eq. 3c) is a function of the volume fractions of the aqueous
phase (/aqueous,1 /aqueous,2) and organic phase (/organic,1
/organic,2)ofbothspaces.TheLogDdescribeshowtheentity
partitions between an organic and aqueous phase of equal
volume(Eq. 3d).ForneutralmoleculestheLogDisthesame
as the LogP. For ionizable molecules, however, the LogD
depends on the pH of the two ﬂuid spaces. The permeability
rate of the entity from the ﬂuid space one to two (P1?2), is a
function of the average diffusion rate out of ﬂuid space one,
P1, across the surface P12, and into ﬂuid space two, P2
(Eq. 3e).Theoverallpermeabilityratefromspaceonetotwo
dependsontheaveragedistanceoftravel,d1,d 12,d 2(deﬁned
in the BioDMET whole body model for each space) and the
diffusioncoefﬁcientsD1,D 12,D 2oftheentityinthetwoﬂuid
spaces and the separating surface. Assuming the surface is a
lipid membrane, the LogD is used to approximate the
probability for a molecule to go from a generally aqueous
environmentintoonethatisalmostentirelyorganic(Eq. 3e).
The diffusion coefﬁcient for each environment is computed
using the Stokes–Einstein equation (Eq. 3f) as a function
of the entities’ hydrodynamic radius (Rh), the viscosity
and the temperature of the ﬂuid (g1, T), and Boltzmann’s
constant (e).
dC1
dt
¼
P2!1S12C2
KpV1
 
P1!2S12C1
V1
ð3aÞ
dC2
dt
¼
P1!2S12C1
V2
 
P2!1S12C2
KpV2
ð3bÞ
1
Kp
¼
Uaqueous;1 þ 10logDðpH1ÞUorganic;1
Uaqueous;2 þ 10logDðpH2ÞUorganic;2
ð3cÞ
logD ¼ log
Corganic
Caqueous
  
ð3dÞ
P1!2 ¼
1
1
P1 þ 1
P12 þ 1
P2
   ¼
1
d1
D1 þ d12
10logDðpH1ÞD12 þ d2
D2
   ð3eÞ
D1 ¼ e
T
6pg1Rh
ð3fÞ
Clearance mechanism
Agents are generally eliminated from the body through
biliary and/or renal excretion either directly or after being
metabolized. For renal clearance, the agent’s excretion rate
is dependent upon the rate at which it is passively ﬁltered
through the kidney’s fenestrated glomerular capillaries and
the rates of secretion and reabsorption across the kidney
tubular epithelium. Within BioDMET, the passive ﬁltration
through the fenestrated glomerular capillaries is modeled
as a ﬁltered pipe (Eq. 2). The convective ﬂow of the pipe,
J1?2, is equivalent to the glomerular ﬁltration rate (GFR)
that depends on the blood ﬂow to the kidney (Qkidney) and
the hematocrit (Ht) as described by Eq. 4a. The glomerular
capillaries of the human model have 8.2 nm diameter pores
[45]. Because of the negative charges lining the surfaces of
the pores, agents with various charges will pass through the
pores at different rates for a given hydrodynamic volume.
The function used to compute the agent’s reﬂection coef-
ﬁcient (Eq. 2c) for neutral agents was empirically derived
based on the effects of size and electrical charge of dextran
on its ﬁlterability by the glomerular capillaries [45]. The
plasma protein binding of the agent is taken into consid-
eration when modeling the ﬁltration process. By default,
active secretion in the proximal tubules and reabsorption in
the distal tubules of free agents are not accounted for.
However, the model can be easily customized to include
these processes once the rates are known or can be esti-
mated. Albumin-bound agents are reabsorbed together with
albumin which is ﬁltered through the pores of the glomeruli
and then are partially reabsorbed through the epithelial
cells lining the proximal tubules [46, 47].
For agents/drugs that are metabolized by the liver,
BioDMET models hepatic clearance using in vitro mea-
sured microsomal clearance rates (Clmicrosomal), although
J Pharmacokinet Pharmacodyn (2012) 39:37–54 43
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clearance rate Clliver, or hepatocyte clearance Clhepatocyte)a r e
also accepted. The relationships between the microsomal
clearance rate and the other measures of liver clearance are
deﬁned by Eqs. 4b–4d, where Vincubate is the incubation
volume, mmicrosomes and nhepatocyte refer to the amount of
microsomes and the number of hepatocytes per gram of liver
tissue, respectively. The in vivo rate of liver metabolism r is
calculated from the in vitro liver microsomal clearance rate
taking into account the mass of the liver (M), the volume of
the space (V) where the metabolic reactions take place, and
the conversion factor (f = 45 mg microsomal proteins/g of
liver [48]) according to Eq. 4e.
GFR ¼ 0:2  ð 1   HtÞ Qkidney ð4aÞ
T1=2 ¼
0:693   Vincubate
Clmicrosomal
ð4bÞ
Clhepatocyte ¼ Clmicrosomal  
mmicrosome
nhepatocyte
ð4cÞ
Clliver ¼ Clmicrosomal   mmicrosome ð4dÞ
r ¼ Clmicrosomal
f   M
V
ð4eÞ
The tool allows the user to select either a ﬁrst order or a
Michaelis–Menten type reaction for describing liver
metabolism. Since in vitro measured liver microsomal or
hepatocyte clearance rates characterize the overall disap-
pearance of the compound in a liver preparation (including
multiple possible metabolic processes as well as diffusion
through membranes) and not just the rate of the individual
enzymatic reactions inside the liver cells, the place of this
biotransformation in BioDMET is the interstitial space of
the liver.
Model parameters and data sources
To populate the physiology models, parameter values have
been obtained from the published literature on mice, rats,
guinea pigs, monkeys, and humans including some speciﬁcs
on strains, age, gender, and body mass index (BMI). The
type of data that has been collected includes: mass/volume
of tissues and size of cells; cardiac output and ﬂow rates of
blood, lymph, bile, chime, urine; surface areas of cellular
membranes including small intestines, proximal tubule
epithelialcellsofthekidneyandhepatocytecanaliculiofthe
liver; water/organic phase content of vascular, interstitial,
and sub-cellular compartments; degree of capillary fenes-
tration for the different organ tissues; distances of travel
within vascular, interstitial, and sub-cellular compartments.
Every parameter deﬁned in a BioDMET model repre-
sents something that can be deﬁned physically and can be
measured independently. For example, each ﬂuid phase has
a deﬁned composition of water, protein, carbohydrate,
lipid, DNA, RNA, mineral, and even air (e.g., alveolus in
lung), allowing the computation of the relative volumes of
the organic and aqueous phases of every space. This, in
turn, is used when computing how a molecule may prefer
one ﬂuid space over another based on the molecules
hydrophobic/hydrophilic characteristics as described by its
LogP/LogD. The alternative approach is to use tissue
partitioning coefﬁcient derived by ﬁtting the model to
experimental in vivo data for each species of interest.
The number and size of clefts and pores between the
endothelial cells are parameters deﬁned for each tissue’s
capillary bed [44, 49–54]. The pores and clefts of the
capillaries have a signiﬁcant impact on the vascular-inter-
stitial permeability for highly charged or moderately high
molecular weight molecules. The alternative approach
would be to use a tissue permeability coefﬁcients derived
by ﬁtting the model to experimental in vivo data. This
empirical approach becomes more difﬁcult since the per-
meability behavior is dependent upon multiple ﬂow pro-
cesses across or between the endothelial cells of the
capillary wall. Because BioDMET deﬁnes the base attri-
butes such a ﬂuid composition, distances between ﬂuid
spaces, pore/cleft surface area and size, more mechanistic
ﬂow equations can be derived. Furthermore the base
attributes can be independently measured and derived and
do not rely on ﬁtting the model to in vivo data.
In addition to the parameters described above, all rele-
vant physico-chemical properties for the agent (molecular
weight, LogP, LogD as a function of pH) are to be speciﬁed
by the user when setting up a simulation. The hydrody-
namic radius is calculated based solely on the molecule’s
physico-chemical characteristics. The diffusion coefﬁcient
is determined using the Stokes–Einstein equation in water
and at body temperature. Corrections are then used to
compute a diffusion coefﬁcient for the interstitial ﬂuid and
the membrane. These corrections are estimates based on
ﬁtting to experimental values of permeability for artiﬁcial
membranes and isolated perfused tissues [55, 56].
Biochemical properties have to be provided as well,
including enzymes that the molecule is a substrate for and
possible metabolites of the parent compound with their
properties. The ability to track the metabolites besides the
parent compound is especially important for imaging since
the radioactive label usually remains attached to one of
them and will inﬂuence the generated image. The term
enzyme in the model is used to describe a protein that can
bind, transport, or catalyze the transformation of the sub-
strate molecule. The kinetic rate parameters for the
enzyme-molecule complex are also expected as part of the
input.
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The BioDMET software tool is composed of three major
parts (Fig. 4):
1. A PBPK model (BioDMET Model) with a database of
host, agent, and pathogen models that can be extended
as necessary and incorporated by users into their
simulations.
2. A model simulator built around an ODE solver.
3. A GUI used to deﬁne, run, and view results of the
PBPK simulator.
The BioDMET database
The BioDMET software is bundled with a set of existing
host, agent, and pathogen models. These models are pre-
built components that can be used to set up a simulation.
They are stored as ﬁles in an XML-compliant markup
language, which was chosen in order to facilitate inter-
change of the model data with other systems/applications.
The data contained in the XML model ﬁles are read
directly by the software. At minimum, a BioDMET run
requires a host ﬁle and an agent ﬁle as the input for a
biodistribution calculation. For a pathogen-host simulation,
an additional pathogen model ﬁle is required. The agent ﬁle
holds all relevant physico-chemical property information
for the exogenous molecule(s) being studied, such as
molecular weight, LogP, and LogD as a function of pH.
This ﬁle also contains biochemical properties of the
molecule, if available, including possible metabolites of the
parent and their properties as well as known enzymes that
the molecule is a substrate for. The term enzyme in the
model is used to describe a protein that can bind, transport,
or catalyze the transformation of the substrate molecule.
The kinetic rate parameters for the enzyme-molecule
complex are speciﬁed in this ﬁle. The host ﬁle holds all the
anatomical, physiological, and cellular parameter data for
the animal or human. All of this information is independent
of the molecule whose biodistribution is studied. This host
ﬁle can also hold the names, concentration, and sub-cel-
lular locations of the enzymes for binding, transporting, or
catalyzing a biotransformation. The existing host models
reﬂect the physiological state of the healthy organism.
However, a disease can signiﬁcantly alter the values of
these parameters, inﬂuencing the distribution of exogenous
agents. Therefore, we developed a database of physiology
parameters for the critically ill and implemented the
capability to model several disease states such as severe
burns, multiple organ failure, etc.
PBPK simulator and ODE solver
As described above, the tool uses ODEs to represent at the
macro scale the circulation of ﬂuid through organs and
tissues, and at the molecular scale the biological transport
mechanisms and biotransformations within cells and their
organelles. The BioDMET GUI passes the Simulation
Input Object Instance on the PBPK Model Simulator. At its
heart, the simulator contains an ODE solver.
Fig. 4 Overview of the
software components and the
simulation process
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input object structure is performed, including validation of
the input parameters for correctness and completeness. As
the simulation runs, the output data augments the input
object instance structure. This can be thought of as a new
object instance structure, called the Simulation Output
Object Instance (Fig. 4). The simulation itself calculates
concentrations of the agent in each of the sampling loca-
tions and at each of the sampling times deﬁned by the
simulation input parameters. This information is stored
along with the original input structure as the output object
instance. Once the simulation completes, this structure is
passed back to the BioDMET GUI tool.
GUI
One of the major components of the BioDMET application
is the GUI, which can be used to create host, agent, and
pathogen models as well as setup and conﬁgure PBPK
simulations. The tool allows users to choose from any of
the host or pathogen models stored in the Model Database,
import them into the tool and modify as needed.
The GUI also provides some basic analysis with means
of graphing simulation results—plots of agent concentra-
tions over time at the various sampling locations in the host
model anatomy. The user can also export the measurement
data to external tools such as Microsoft Excel. Further-
more, the output of the simulation can be saved in XML
form on the user’s ﬁle system. This data can be used as
input to other applications for post processing, analysis,
and reporting. Simulation results from previous runs can be
reloaded into the BioDMET GUI tool, modiﬁed as needed,
and then rerun for comparative analysis.
There are three main sections to the user interface: the
model tree view—displaying the simulation conﬁguration
information in a hierarchical view, the property window—
which displays property sheets for the currently selected
item(s) in the hierarchy display, and the information win-
dow—which provides access to additional information on
the simulation setup and results (Fig. 5).
Setting up and running a simulation
The website
BioDMET has a web site (https://pdsl.research.ge.com/
BioDMET/) hosted by GE Global Research that allows
easy access to the latest release of the tool, tutorials, doc-
umentation and nonproprietary models, test data, notes and
references (Supplementary Fig. S1). Users can run the
application via a standard web browser over the Internet.
Access to the program is granted after a one-time regis-
tration requiring the user to provide a name, afﬁliation and
e-mail address. Currently, all user-generated models and
data are stored on the client’s computer disk storage and
NOT on the GE hosting server.
Wizards
Setting up a PBPK simulation with BioDMET involves
multiple steps including constructing the host model hier-
archy,creatingthepipeandsurfaceconnectionsbetweenthe
spaces in the hierarchy, deﬁning the enzyme and pathogen
types and their concentrations in the appropriate spaces in
the host model, specifying the agents to be administered
along with the method of administration and the amount
being administered, the sampling time points and locations,
as well as deﬁning a pharmacodynamic function with its
necessary parameters. This can be a daunting task. To make
it easier, BioDMET includes a number of pre-deﬁned host/
species, agent, and pathogen models which can be added to
the simulation setup and customized as needed. In addition,
several wizards have been designed to guide the user
through the process of creating a new pathogen model,
setting up a new biodistribution (PK) simulation or a new
pathogen-host (PK-PD) simulation, performing sensitivity
analysisoracritically-illpatientanalysis.Thewizardsallow
a user to deﬁne a new simulation more-or-less from scratch
without having to possess a mental map of the simulation
setup and without being aware of the ﬁne details of the
host’s physiological model structure. During this guided
process, the user can import and modify existing host/spe-
cies, agent, and/or pathogen models from the BioDMET
model database. Alternatively, new hosts, agents, and/or
pathogens can also be built. In either case, the wizard guides
the user through the process of deﬁning the key parameters
for the simulation in a step-by-step fashion (Supplementary
Fig. S2). Detailed step-by-step tutorials can be found at the
BioDMET web site under User Guide, which provide
examples for going through the wizards for setting up and
running the different simulation types implemented in
BioDMET.Inaddition,allfunctionalitiesofthesoftwareare
described in the user manual accessible on the above-men-
tioned web site.
Create a new pathogen model This wizard does not
actually result in the creation of a new simulation. Rather,
it allows a user to deﬁne a new pathogen model and save it
to a ﬁle on the ﬁle system. The pathogen model ﬁle can
subsequently be read in and used to create a new simulation
involving a pathogen-infected host.
New biodistribution simulation and new pathogen-host
simulation These wizards guide the user through the
process of creating a simulation model containing a host
animal and an agent/drug whose distribution through the
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simulation, a pathogen is added to the system and a phar-
macodynamic model is selected for computing the changes
in the pathogen load over time.
Sensitivity analysis Disease states are typically charac-
terized by wide inter-patient variability in regard to patient
conditions. Sensitivity analysis implemented in BioDMET
allows the user to estimate the effect of variations in the
model input parameters on the main pharmacokinetic
parameters of the agent of interest. This is achieved by
performing multiple simulations in which one or multiple
input parameters (X-s) are changed and the resulting
variations in the output parameters (Y-s) are monitored.
The program computes a sensitivity coefﬁcient as the ratio
of the change in Y for a given change in X. This infor-
mation can then be used to identify key parameters that
have major inﬂuence on the drug pharmacokinetics and
pharmacodynamics. Sensitivity analysis can also provide a
quick estimate of how model predictions may change
across populations and how drug dosage should be adjusted
for achieving the desired effect. The sensitivity analysis
wizard guides the user through the selection of input
parameters to be varied within user-deﬁned ranges, the type
of simulations (varying one or multiple parameters at a
time), the number of Monte Carlo steps, and the output
parameters to be monitored.
Critically ill patient analysis The BioDMET model
parameters were retrieved from the scientiﬁc literature and
reﬂect the physiological state of the healthy organism. To
account for disease-caused alterations of the normal
physiology that can inﬂuence the distribution of exogenous
agents, we assembled a database of physiology parameters
for the critically ill based on literature data and imple-
mented the capability to model several pathological states
such as high fever, severe burns, multiple organ failure, etc.
Disease states are typically characterized by wide inter-
patient variability in regard to patient conditions. The
Critically Ill Patient Analysis implemented in BioDMET
allows the user to estimate the effect of variations in the
patient conditions on the main pharmacokinetic parameters
of the agent of interest. This information can then be used
to adjust the drug dosage to achieve the desired effect. The
analysis is analogous to a population study where the
individual variations are simulated by Monte Carlo sam-
pling of host parameter values between disease-speciﬁc
limits. These limits are established based on literature
values that are described in the Critically Ill Database
available at the BioDMET website under Downloads.
Simulation output
Once a biodistribution or pathogen-host simulation is
completed, the results are displayed in a dialog window
arranged in a tabular form. Concentration values for the
speciﬁed agents are given for each sampling time and
location as a percentage of the injected dose. The data can
be copied to the clipboard and then pasted into a tool such
as MS Excel for performing further analysis. Another way
to examine the results is by displaying the concentration–
time curves in the Information Window of the GUI. The
Fig. 5 The BioDMET GUI
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to visualize how concentrations of elements of interest
change over time in various tissues and spaces of interest.
If more sophisticated visualization and/or in depth analysis
of the results is needed, the user can export part of or all the
simulation results into a tab-delimited or comma-separated
ﬁle that can then be imported into another software, such as
Excel or Origin. The entire model can be saved in an xml
ﬁle format deﬁned for the BioDMET application. This ﬁle
contains both the setup information and the simulation
results.
In addition to providing the agent biodistribution data,
the following PK parameters are calculated and displayed
at the GUI in the Property Window under the PK Properties
tab after each simulation: maximum concentration (Cmax),
time when the maximum concentration is achieved (tmax),
area under the curve (AUC) calculated using the trapezoid
method from time 0 to the last sampling time point as well
as from time 0 to inﬁnity, mean residence time (MRT), half
life (t1/2), initial concentration (C0), central compartment
volume (Vc), volume of distribution at steady state (Vss),
and clearance (Cl). Except for Cmax,t max, and C0, the other
PK parameters have been derived using a noncompart-
mental approach [57]. This is based on calculating the
AUC of the concentration versus time plot by numerical
integration using the trapezoidal rule.
When experimental time-concentration data is present in
the model, the above listed PK parameters are derived based
on this data as well and are shown under ‘‘MEASURED
CURVE PARAMETERS’’ for comparison. A note of cau-
tion: even when the experimental data points align closely
with the curve representing the calculated drug concentra-
tions, there could be signiﬁcant discrepancies between the
two sets of PK parameters. Most likely, this is due to the fact
that experimental data is usually not available for the early
time points right after the administration of the agent when
drug concentrations change rapidly in time.
After setting up a system with the help of one of the
wizards, it is possible to modify the host, pathogen or agent
at the GUI. These modiﬁed models can be saved as new
host, pathogen or agent ﬁles in xml format for subsequent
simulations.
At the end of each sensitivity analysis or critically ill
patient analysis, a window is shown with a summary of the
analysis results for a quick assessment. For each monitored
output parameter, a bar graph is plotted showing its values
for each set of input parameter values sampled. Plots of the
sensitivity coefﬁcients of each monitored output relative to
the input parameters are also provided after a sensitivity
analysis. These summary plots can be saved into a report
ﬁle in pdf format. This summary is in addition to the text
ﬁle containing the raw output that is generated for each of
these simulations.
Results of testing and validation
Evaluation of predictive capability
The BioDMET software’s ability to predict drug concen-
trations has been validated using a series of 26 drugs/agents
in 44 individual human and animal models. The calculated
agent concentrations at various time points were compared
to experimentally measured concentrations obtained from
the scientiﬁc literature. The literature data search was
performed to cover multiple host species (human, monkey,
guinea pig, rat, mouse) and agent types (drugs, imaging
agents) with a wide range of values of pharmacokinetically
relevant properties such as molecular weights, LogP, and
plasma protein binding (Table 1). Even though BioDMET
has the capability to model multiple modes of adminis-
tration (intravenous, intramuscular, subcutaneous, and
oral), the majority of the experimental data collected was
based on IV administration. A more comprehensive testing
and validation of the other administration methods is the
focus of a continuing effort.
Good correlation was obtained between experimentally
measured and calculated log concentrations of drugs/agents
in plasma (R
2 = 0.93) and in various other tissues
(R
2 = 0.89, Fig. 6) following IV administration. The stan-
darddeviationoftheLog10(measured/calculated)ratioswas
0.39withameanvalueof0.08fortheplasma,and0.45witha
mean value of 0.13 for the tissues. This level of predictive
accuracy is similar to that found in other PBPK models [20].
The individual calculated time-concentration curves com-
pared to the experimental data can be downloaded from the
tool website (the link is provided under Validation).
The tool was able to account for the differences in the
plasma/muscle and plasma/skin concentration ratios mea-
sured for two cephalosporin antibiotics, cefpirome and
cefodizime, in healthy volunteers (Fig. 7). This has been
attributed mainly to the large differences in plasma protein
binding of the two drugs [58]. Similarly, the simulated
effect of varying renal function on the plasma concentra-
tion of iohexol was in good agreement with the experi-
mentally observed trend (Fig. 8). The validation data
(PBPK model parameters, calculated and measured data,
including references) is available at the BioDMET web site
(http://pdsl.research.ge.com/BioDMET/).
Discussion
The development of BioDMET has been driven by the
need to perform feasibility calculations when faced with
complex problems where the interplay of multiple vari-
ables can affect the output in a nonlinear fashion. These
types of calculations can provide a feel for the magnitude
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started. They can also highlight the most problematic areas
or the ones where critical data is missing. As more and
more experimental data becomes available, the models can
be reﬁned to provide more accurate predictions and help
explain sometimes unexpected results.
One of the main application areas is assessing the im-
ageability of certain anatomical or disease conditions and
delineating the property space of the imaging agent and of
the target that could produce images of acceptable quality.
The other area is that of drug development. The question
here is whether or not a drug candidate could reach the
target tissue in high enough concentrations long enough to
produce a therapeutic effect while producing minimal
toxicity in tissues that are most susceptible.
Establishing imageability criteria
The system model illustrated in Fig. 9 provides the capa-
bility to calculate the expected in vivo clinical images for a
set of input properties of the biomarker, imaging agent, and
disease state [60]. It is composed of the whole-body PBPK
model BioDMET, whole body anatomical maps, and ana-
lytical and Monte Carlo image simulator codes for positron
emission tomography (PET) and single photon emission
computed tomography (SPECT). The input includes ana-
tomical and physiological information about the host and
the disease state of interest, physico-chemical as well as
biological properties of the agent and its in vivo target.
BioDMET calculates the in vivo concentrations of the
examined imaging agent in all major body tissues over time,
which is used to compute the time-activity curves of a radio-
labeled agent. This is then used as the input, along with
detailed 3D anatomy phantoms of the human or animal sub-
ject, into the physics-based imaging simulator to generate
imagesshowinghowthepotentialimagingagentwouldwork.
The images are processed just like actual measured images,
delineating the regions of interest and quantifying the signal.
The process is run somewhat in reverse during feasi-
bility assessments. Starting with the clinical need for
Table 1 Summary of model validation data sets collected
Drug or agent MW LogP PPB (%) Human Rhesus monkey Guinea pig Rat Mouse
1 99mTc-DTPA 491.4 -6.5 – BioD
2 Acetaminophen 151.2 0.5 20 PP
3 Acyclovir 225.2 -1.0 33 P
4 Amoxicillin 365.4 -4.0 20 P
5 Atorvastatin 558.6 5.4 98 P
6 Azathioprine 166.2 0.9 20 P
7 Caffeine 194.2 -0.5 30 P
8 Cefodizime 584.7 0.2 70 P, U, M, S, B
9 Cefozopran 516.5 -3.0 8 P, U BioD BioD BioD
10 Cefpirome 515.6 -4.1 10 P, M, S, L
11 Diazepam 284.7 3.1 98.5 BioD
12 Fexofenadine 501.7 0.9 65 P
13 Inulin 6179.4 -18.0 – P, U
14 Iohexol 821.1 -4.2 – P (Renal)
15 Iopromide 791.1 -3.0 – P
16 Ketoconazole 531.4 4.2 99 P
17 Mannitol 182.2 -3.7 – P
18 Midazolam 325.8 3.1 97 PP
19 Nateglinide 317.4 4.0 98 P
20 Propranolol 259.3 2.6 90 BioD
21 SU5416 (Semaxanib) 238.3 3.0 – P
22 Theophylline 180.2 -0.8 48 P
23 Troglitazone 441.5 5.5 99 P
24 Velcade 384.2 1.5 83 P
25 Verapamil 454.6 5.0 95 PP
26 Zidovudine (AZT) 267.2 -2.4 31.5 P
Italic boxes correspond to existing experimental data. The deﬁnition of letter symbols: BioD full biodistribution in all major organ tissues,
B bone, M muscle, L lung, P plasma, S skin, U urine, Renal renal function data available
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123visualizing a speciﬁc pathological condition, the properties
of the radio-pharmaceutical and target biomarker are
derived to meet the imaging requirements for resolution,
speciﬁcity, and sensitivity given the inherent noise and
limitations of an imaging system and protocol. This is
accomplished by running multiple calculations with clini-
cally relevant disease and healthy physiology parameters,
types and property ranges of the imaging agent and bio-
marker to be evaluated, as well as the scoring criteria for a
good image (e.g., target to background signal at a deﬁned
time post injection of the agent). The software then eval-
uates the performance of different possible combinations of
target biomarker and agent biochemical properties against
the scoring criteria. Target biomarker properties include its
location and concentration levels throughout the body as
well as changes with disease progression. Agent properties
include molecular weight, LogP/LogD, plasma protein
binding, clearance rates, and agent-target binding strength
and rate. Imaging requirements such as imaging time post
injection and degradation of the signal due to scatter and
spillover effects are also considered. In a typical assess-
ment, over 60,000 biodistribution calculations are per-
formed, scored for imaging feasibility, and plotted on
color-coded imageability maps (shown in grayscale in
Fig. 9). These maps are then used to assess the feasibility
of imaging a speciﬁc disease for all of the given agent-
target pairs. One example of such a feasibility study was
performed to assess the possibility of detecting lesions in
the brain of patients with multiple sclerosis using PET
imaging [61].
Evaluating drug efﬁcacy and dosing
The main purpose of PBPK modeling is to combine a
complex model of an organism with in vitro measurable
properties of an agent or drug and predict how it will behave
in vivo. This can be taken one step forward by adding
further information to the model about the therapeutic and
toxic properties of the drug: the effective concentration
above which it has measurable therapeutic effects and the
toxic concentration at which various toxic effects become
detectable. The PBPK model can then be used to estimate
the range of doses at which the concentration of the drug in
the target tissue can be kept above the effective concen-
tration while keeping it below the toxic levels in tissues that
are most prone to damage. This could be more reliable and
more speciﬁc than the standard in vitro therapeutic index
because it can include individualized information about the
patient population (age, weight, health status) as well as
drug concentrations at target tissues.
Unique features of BioDMET
Setting up a PBPK model and running a simulation used to
be a time-consuming, tedious process that required a large
number of parameters to be speciﬁed and code writing for
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50 J Pharmacokinet Pharmacodyn (2012) 39:37–54
123solving differential equations. These types of calculations
were accessible typically only to scientists trained in this
ﬁeld. BioDMET is designed to overcome these challenges
by providing a scientiﬁcally rigorous yet easy-to-use tool
with complete, parameterized PBPK models for several
species that can be easily customized without the need for
programming skills.
The models are comprised of spaces that correspond to
real anatomical entities (vasculature, interstitial space,
CSF, urine, lymph, subcellular compartments) and are
grouped naturally by anatomical organs and tissues. There
is no need for artiﬁcial compartments that lump together
several distinct tissues or organs in order to explain the
kinetics of the drug. As a consequence, drug concentrations
can be calculated in any of these anatomically relevant
spaces and compared to experimentally measured values to
validate the model. This also enables the calculation of
drug concentration directly at the place of the action for
pharmacodynamic evaluations instead of having to use the
plasma concentration as a proxy.
Open access to all of the physiology model parameters
and rate constants are provided with the human and animal
models. References to the model parameters can be
accessed through the software GUI under the Notes icon or
from the tool documentation provided at the tool’s web site
under User Guide. A set of experimental data collected
from the literature with the corresponding references are
also available via the tools web site under Validation. This
way the users can experiment with the tools and can run
their own testing and validation. Even though the simula-
tions are initiated through a web server, the calculations are
done and the results are kept on the user’s computer. No
data is returned to the server assuring complete data
conﬁdentiality.
Customizing/expanding the model
As more and more experimental data becomes available
about the mechanisms involved in the biodistribution and
action of pharmaceutical agents, the need arises to reﬁne
the existing PBPK models by incorporating the new ﬁnd-
ings. BioDMET was built keeping in mind the need to
customize the models for a speciﬁc problem and incorpo-
rate new knowledge. These modiﬁcations can be performed
Fig. 7 Simulated and measured
concentrations of cefpirome and
cefodizime in human plasma,
the interstitial space of muscle,
and skin. The experimental data
is taken from the published
work of Muller et al. [58]
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123in an intuitive fashion at the GUI without the need to
change the code. The customized models can be saved for
later use. New spaces can be added or old ones split into
multiple components and the parameters characterizing this
new space can be changed. New connections can be
established between spaces or existing ones can be modi-
ﬁed. This is how a tumor, for example, can be inserted into
a speciﬁc location of a tissue. The host physiology can also
be altered to model inter-individual differences or changes
caused by disease states. While many of the model
parameter values can be changed in an individual fashion,
some physiology alterations require a concerted change
across multiple organs and tissues because the organism is
a closed system and the sum of certain quantities is ﬁxed.
For example, tissue inﬂammation can be modeled by
specifying the volume fraction of the inﬂamed tissue and
adjusting the blood and lymph ﬂow, the vascular perme-
ability and change in tissue volume due to edema at a
dialog window (Supplementary Fig. S3). After such a
change, the tool will make the necessary adjustments to all
other spaces connected when the biodistribution of the
pharmaceutical is recalculated.
While the pharmacokinetics of some drugs can be
modeled quite accurately by passive diffusion and a simple
Fig. 8 Simulations versus
measurements for iohexol in
human plasma for single
patients with different renal
functions. Experimental data
points were taken from the
published work of Gaspari et al.
[59]. The GFR varies from
healthy function of 115.7 ml/
min/1.73 m
2 to renal failure rate
of 8.9 ml/min/1.73 m
2
Fig. 9 Computational system
model for assessing imaging
feasibility. The lighter the color
of the box on the imageability
map, the higher the probability
that the corresponding property
combinations lead to successful
imaging
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123one-step liver metabolism, others require a complex
interplay of enzymes and transporters. BioDMET allows
adding transporters and enzymes and offers two
alternatives to describe the process: ﬁrst order or
Michaelis–Menten type equation. The user has to specify
the necessary parameters including the location and con-
centration of the enzyme or transporter, the substrate, the
rate of the process, the origin and destination space, the
creation and destruction rate of the enzyme, etc. Since
the model can track multiple agents and their metabolites,
drug–drug interactions can also be taken into account. More
details on how to implement such changes are described in
the user manual downloadable from the tools’ website.
As new therapeutic platforms appear, there is a need for
PBPK models to handle peptides, proteins, nucleotides and
nanoparticles. It is possible to implement the simulation of
these agents in BioDMET. At this point, however, the user
has to be aware of the mechanistic differences relative to
small molecule drugs that are important for the biodistri-
bution of these molecules, and provide the necessary
parameters characterizing the processes involved, includ-
ing diffusion, transport, metabolism, etc.
Future work is aimed at parameterizing and validating
BioDMET for the various therapeutic platforms, including
the most frequently encountered transporters into the
model, and allowing user-deﬁned equations for describing
enzyme- and transporter-mediated processes.
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